Bilgin and coworkers1 recently reported a significant decrease in mortality in septic neutropenic neonates treated with granulocyte-macrophage colony-stimulating factor (GM-CSF). We wish to call in question the methodology and handling of statistics in their study. The trial was neither placebo-controlled nor double-blinded, and in addition the reader gets the impression that the randomization was not concealed. Indeed: "Patients were assigned alternatively to the rhGM-CSF or control groups according to their order of admission." Because only a P value of <.05 and no confidence intervals (CIs) were reported, we reanalyzed the raw data.2 The power of the performed
2 test with
= .05
This article has been cited by other articles:
![]() |
A G De Paoli, C Morley, and P G Davis Nasal CPAP for neonates: what do we know in 2003? Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2003; 88(3): F168 - F172. [Abstract] [Full Text] [PDF] |
||||